Decision: Favourable

Study Title:

A Phase 3, Two-Stage, Randomized, Multicenter, Open Label Study Comparing CC-92480, Bortezomib and Dexamethasone (480Vd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM)

  • NREC Code:


  • Decision:


  • Meeting Date:


  • Study Type:

    CT Application

  • Principal Investigator:

    Dr Patrick Hayden

  • PI Institution:

    St James's Hospital

  • Sponsor:

    Celgene Corporation

Scroll to Top
Skip to content